| http://www.w3.org/ns/prov#value | - ROCKVILLE, Md., Dec. 13, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, today announced the exercise of the over-allotment option granted to the underwriters to purchase an additional 1,725,000 shares of its common stock, at a price to the public of $1.00 per share,
|
